Loss-of-function CYP2C9 variants: Finding the correct clinical role for type 2 diabetes pharmacogenetic testing

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 3, 2010, Pages 339-343

  Grant, Richard W ^a   Wexler, Deborah J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cytochrome P450 enzyme; Genetic polymorphisms; Personalized medicine; Pharmacogenetics; Sulfonylureas; Type 2 diabetes

Indexed keywords

CYTOCHROME P450 2C9; HEMOGLOBIN A1C; SULFONYLUREA DERIVATIVE;

CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PHARMACOGENETICS; QUANTITATIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BLOOD GLUCOSE; COHORT STUDIES; CONFIDENCE INTERVALS; CYTOCHROME P-450 ENZYME SYSTEM; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; PROBABILITY; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 77949431150     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.5     Document Type: Note

References (24)

1. Zhou K, Donnelly L, Burch L et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in Type 2 diabetes: a Go-DARTS study. Clin. Pharmacol. Ther. 87(1), 52-56 (2010).
2. Kirchheiner J, Bauer S, Meineke I et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12(2), 101-109 (2002).
3. Kirchheiner J, Brockmoller J, Meineke I et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther. 71(4), 286-296 (2002).
4. Pearson ER, Donnelly LA, Kimber C et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTS study. Diabetes 56(8), 2178-2182 (2007).
5. Zhou K, Donnelly LA, Kimber CH et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 58(6), 1434-1439 (2009).
6. Gloyn AL, Pearson ER, Antcliff JF et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 350(18), 1838-1849 (2004).
7. Pearson ER, Flechtner I, Njolstad PR et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med. 355(5), 467-477 (2006).
8. Meigs JB, Shrader P, Sullivan LM et al. Genotype score in addition to common risk factors for prediction of Type 2 diabetes. N. Engl. J. Med. 359(21), 2208-2219 (2008).
9. Grant RW, Moore AF, Florez JC. Genetic architecture of Type 2 diabetes: recent progress and clinical implications. Diabetes Care 32(6), 1107-1114 (2009).
10. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
11. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1), 193-203 (2009).
12. Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008).
13. Schwarz UI, Ritchie MD, Bradford Y et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358(10), 999-1008 (2008).
14. Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009).
15. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
16. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 22(15), 2025-2033 (2008).
17. Park L, Wexler D. Update in diabetes and cardiovascular disease: synthesizing the evidence from recent trials of glycemic control to prevent cardiovascular disease. Curr. Opin. Lipidol. 21(1), 8-14 (2010).
18. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of Type 2 diabetes. Diabetes Care 26(9), 2518-2523 (2003).
19. Grant RW, Hivert M, Pandiscio JC, Florez JC, Nathan DM, Meigs JB. The clinical application of genetic testing in Type 2 diabetes: a patient and physician survey. Diabetologia 52(11), 2299-2305 (2009).
20. Burke W, Psaty BM. Personalized medicine in the era of genomics. JAMA 298(14), 1682-1684 (2007).
21. Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA 299(11), 1320-1334 (2008).
22. Joy MS, Dornbrook-Lavender K, Blaisdell J et al. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Eur. J. Clin. Pharmacol. 65(9), 947-953 (2009).
23. Agundez JA, Garcia-Martin E, Martinez C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin. Drug Metab. Toxicol. 5(6), 607-620 (2009).
24. Gold LS, De Roos AJ, Brown EE et al. Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma. Cancer Epidemiol. 33(3-4), 276-280 (2009).